| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Julie J Miller, Helen A Shih, Ovidiu C Andronesi, Daniel P Cahil. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications. Cancer. vol 123. issue 23. 2017-12-05. PMID:28980701. |
these mutations co-occur with other recurrent molecular alterations, including 1p/19q codeletions and tumor suppressor protein 53 (tp53) and alpha thalassemia/mental retardation (atrx) mutations, which together help to define a molecular signature that aids in the classification of gliomas and helps to better predict clinical behavior. |
2017-12-05 |
2023-08-13 |
Not clear |
| Manav Pathania, Nicolas De Jay, Nicola Maestro, Ashot S Harutyunyan, Justyna Nitarska, Pirasteh Pahlavan, Stephen Henderson, Leonie G Mikael, Angela Richard-Londt, Ying Zhang, Joana R Costa, Steven Hébert, Sima Khazaei, Nisreen Samir Ibrahim, Javier Herrero, Antonella Riccio, Steffen Albrecht, Robin Ketteler, Sebastian Brandner, Claudia L Kleinman, Nada Jabado, Paolo Salomon. H3.3 Cancer cell. vol 32. issue 5. 2017-11-27. PMID:29107533. |
h3.3 gain-of-function mutations in histone 3 (h3) variants are found in a substantial proportion of pediatric high-grade gliomas (phgg), often in association with tp53 loss and platelet-derived growth factor receptor alpha (pdgfra) amplification. |
2017-11-27 |
2023-08-13 |
mouse |
| Joan J Castellano, Alfons Navarro, Nuria Viñolas, Ramon M Marrades, Jorge Moises, Anna Cordeiro, Adela Saco, Carmen Muñoz, Dolors Fuster, Laureano Molins, Josep Ramirez, Mariano Monz. LincRNA-p21 Impacts Prognosis in Resected Non-Small Cell Lung Cancer Patients through Angiogenesis Regulation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. vol 11. issue 12. 2017-11-13. PMID:27496652. |
long intergenic noncoding rna-p21 (lincrna-p21) is a long noncoding rna transcriptionally activated by tumor protein p53 (tp53) and hypoxia inducible factor 1 alpha subunit (hif1a). |
2017-11-13 |
2023-08-13 |
Not clear |
| Matthias B Stope, Dominique Koensgen, Jörg Weimer, Madeleine Paditz, Martin Burchardt, Dirk Bauerschlag, Alexander Muste. The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical application. Archives of gynecology and obstetrics. vol 294. issue 5. 2017-08-09. PMID:27637583. |
the available biomarkers, such as cellular tumor antigen p53 (tp53), phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase (pten), and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (pik3ca) genes alone might not be sufficient, and thus, new predictive and prognostic biomarkers are urgently required. |
2017-08-09 |
2023-08-13 |
Not clear |
| Ricky Chen, Adam L Cohen, Howard Colma. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. Current treatment options in oncology. vol 17. issue 8. 2017-08-07. PMID:27334978. |
molecular categorization of glioma subtypes using mutations in isocitrate dehydrogenase 1/2 (idh1/2), tp53, and atrx; codeletion of chromosomes 1p and 19q; dna methylation; and amplification of genes such as epidermal growth factor receptor (egfr) and platelet-derived growth factor receptor, alpha polypeptide provides a more accurate prognostication and biologic classification than classical histopathological diagnoses, and a number of molecular markers are being incorporated in the new world health organization classification of gliomas. |
2017-08-07 |
2023-08-13 |
Not clear |
| Sapan J Patel, Gaurang L Trivedi, Costel C Darie, Bayard D Clarkso. The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer. Journal of cellular and molecular medicine. vol 21. issue 3. 2017-07-17. PMID:27680505. |
we found that bcnp1 is highly altered in some types of cancers and that bcnp1 copy-number changes and mutations co-occur with other molecular alteration events for tp53 (tumour protein p53), pik3ca (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha), mapk1 (mitogen-activated protein kinase-1; erk: extracellular signal regulated kinase), kras (kirsten rat sarcoma viral oncogene homolog) and akt2 (v-akt murine thymoma viral oncogene homolog 2). |
2017-07-17 |
2023-08-13 |
rat |
| Ajay Chaurasia, Sung-Hye Park, Jeong-Wook Seo, Chul-Kee Par. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival. Journal of Korean medical science. vol 31. issue 8. 2017-02-22. PMID:27478330. |
here, we classified our cohort of 163 adult gbms into molecular subgroups according to the expression of proteins encoded by genes of alpha thalassemia/mental retardation syndrome x-linked (atrx), isocitrate dehydrogenase (idh) and tp53. |
2017-02-22 |
2023-08-13 |
Not clear |
| Yuntao Lu, Limin Xiao, Yawei Liu, Hai Wang, Hong Li, Qiang Zhou, Jun Pan, Bingxi Lei, Annie Huang, Songtao Q. MIR517C inhibits autophagy and the epithelial-to-mesenchymal (-like) transition phenotype in human glioblastoma through KPNA2-dependent disruption of TP53 nuclear translocation. Autophagy. vol 11. issue 12. 2016-10-31. PMID:26553592. |
furthermore, following treatment with the autophagy inducer temozolomide (tmz) and low glucose (lg), mir517c degraded kpna2 (karyopherin alpha 2 [rag cohort 1, importin alpha 1]) and subsequently disturbed the nuclear translocation of tp53 in the gbm cell line u87 in vitro. |
2016-10-31 |
2023-08-13 |
mouse |
| Netta Mäkinen, Mervi Aavikko, Tuomas Heikkinen, Minna Taipale, Jussi Taipale, Riitta Koivisto-Korander, Ralf Bützow, Pia Vahterist. Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12. PLoS genetics. vol 12. issue 2. 2016-07-12. PMID:26891131. |
most frequently mutated genes included tumor protein p53 (tp53; 6/19; 33%), alpha thalassemia/mental retardation syndrome x-linked (atrx; 5/19; 26%), and mediator complex subunit 12 (med12; 4/19; 21%). |
2016-07-12 |
2023-08-13 |
Not clear |
| Chun-Ting Kuo, Chieh Chang, Wen-Sen Le. Folic acid inhibits COLO-205 colon cancer cell proliferation through activating the FRα/c-SRC/ERK1/2/NFκB/TP53 pathway: in vitro and in vivo studies. Scientific reports. vol 5. 2016-04-12. PMID:26056802. |
knock-down of folate receptor alpha (frα) abolished fa-induced activations in the c-src-mediated pathway and increases in the levels of cdkn1a, cdkn1b and tp53 protein. |
2016-04-12 |
2023-08-13 |
Not clear |
| Hou-Jun Xia, Bao-Li He, Chun-Yan Wang, Hai-Lin Zhang, Guang-Zhe Ge, Yuan-Xu Zhang, Long-Bao Lv, Jian-Lin Jiao, Ceshi Che. PTEN/PIK3CA genes are frequently mutated in spontaneous and medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumours of tree shrews. European journal of cancer (Oxford, England : 1990). vol 50. issue 18. 2015-01-27. PMID:25457635. |
the pten/pik3ca (phosphatase and tensin homologue/phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), but not tp53 and gata3, genes are frequently mutated in breast tumours, and the pten/pik3ca gene mutation status correlated with the expression of pakt in tree shrew breast tumours. |
2015-01-27 |
2023-08-13 |
human |
| Manuel Rieber, Mary Strasberg-Riebe. p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptility to 3-bromopyruvate in ERα+ breast cancer MCF-7 cells. Biochemical pharmacology. vol 88. issue 2. 2014-04-22. PMID:24486524. |
most breast cancers express the estrogen receptor alpha (erα(+)), harbor wt tp53, depend on estrogen/erk signalling for proliferation, and respond to anti-estrogens. |
2014-04-22 |
2023-08-12 |
Not clear |
| Vijaya Galic, Robert L Coleman, Thomas J Herzo. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Current cancer drug targets. vol 13. issue 6. 2014-03-18. PMID:23675882. |
areas specifically addressed include hormonal pathways, tumor protein p53 (tp53) and at rich interactive domain 1a (swi-like; arid1a) mutation, and the breast cancer 1/2, early onset (brca1/2) mutation/poly (adp-ribose) polymerase 1 (parp1), phosphatidylinositol-4,5-bisphosphate 3- kinase, catalytic subunit alpha (pi3kca)/v-akt murine thymoma viral oncogene homolog 1 (akt1)/mechanistic target of rapamycin (mtor), and mitogen-activated protein kinase kinase 1 and 2 (map2k1/2) pathways. |
2014-03-18 |
2023-08-12 |
Not clear |
| D Figarella-Branger, A Maues de Paula, C Colin, C Bouvie. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Revue neurologique. vol 167. issue 10. 2012-01-26. PMID:21889777. |
interestingly, p53 expression and internexin alpha (ina) expression can replace to some extent tp53 mutation and 1p19 codeletion, respectively. |
2012-01-26 |
2023-08-12 |
Not clear |
| M Berglund, N Zainuddin, U Thunberg, G Enbla. Is a TNF alpha polymorphism responsible for mutations in the TP53 gene? Scandinavian journal of immunology. vol 73. issue 2. 2011-01-31. PMID:21198757. |
is a tnf alpha polymorphism responsible for mutations in the tp53 gene? |
2011-01-31 |
2023-08-12 |
Not clear |
| Benjamin Berger, David Capper, Dieter Lemke, Philipp-Niclas Pfenning, Michael Platten, Michael Weller, Andreas von Deimling, Wolfgang Wick, Markus Weile. Defective p53 antiangiogenic signaling in glioblastoma. Neuro-oncology. vol 12. issue 9. 2010-12-02. PMID:20504876. |
p53 responsiveness of the angiogenesis-related target genes, such as vascular endothelial growth factor (vegf), basic fibroblast growth factor (bfgf), thrombospondin 1 (tsp-1), brain-specific angiogenesis inhibitor 1 (bai1), and collagen prolyl-4-hydroxylase alpha 2 (p4ha2), was evaluated by (i) overexpression of wild-type p53 in homozygously tp53-deleted ln-308 cells; (ii) shrna-mediated p53 knockdown in the tp53 wild-type lnt-229 cells; and (iii) chemical induction of wild-type p53 expression in lnt-229 cells by camptothecin. |
2010-12-02 |
2023-08-12 |
Not clear |
| David Dimmock, Lin-Ya Tang, Eric S Schmitt, Lee-Jun C Won. Quantitative evaluation of the mitochondrial DNA depletion syndrome. Clinical chemistry. vol 56. issue 7. 2010-07-08. PMID:20448188. |
mutations in at least 9 genes [polg, polymerase (dna directed), gamma; dguok, deoxyguanosine kinase; tk2, thymidine kinase, mitochondrial; tymp, thymidine phosphorylase; mpv17, mpv17 mitochondrial inner membrane protein; sucla2, succinate-coa ligase, adp-forming, beta subunit; suclg1, succinate-coa ligase, alpha subunit; rrm2b, rrm2b, ribonucleotide reductase m2 b (tp53 inducible); and c10orf2, chromosome 10 open reading frame 2 (also known as twinkle)] have been reported to cause mtdna depletion. |
2010-07-08 |
2023-08-12 |
Not clear |
| Ian R Radford, Pavel N Lobachevsk. Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis. Mutation research. vol 646. issue 1-2. 2009-01-06. PMID:18824008. |
we used statistical analyses to search for sets of dinucleotide sequences (designated target sequences) that are present at and in close proximity to mutation sites in four genes associated with human colorectal tumourigenesis (adenomatosis polyposis coli (apc), v-ki-ras2 kirsten rat sarcoma viral oncogene homolog (kras), phosphoinositide-3-kinase, catalytic, alpha polypeptide (pik3ca), and tumour protein p53 (tp53)). |
2009-01-06 |
2023-08-12 |
human |
| Katarzyna Kokoszynska, Jerzy Ostrowski, Leszek Rychlewski, Lucjan S Wyrwic. The fold recognition of CP2 transcription factors gives new insights into the function and evolution of tumor suppressor protein p53. Cell cycle (Georgetown, Tex.). vol 7. issue 18. 2008-11-03. PMID:18787404. |
the employed procedure clearly shows that the family adopts a dna binding immunoglobulin fold homologous to the p53 (tp53) core domain, and a novel type of ubiquitin-like domain and a sterile alpha motif (sam) form oligomerization modules. |
2008-11-03 |
2023-08-12 |
human |
| A H G Cleven, B G Wouters, B Schutte, A J G Spiertz, M van Engeland, A P de Bruïn. Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis. British journal of cancer. vol 99. issue 5. 2008-09-17. PMID:18728663. |
poorer survival of hif-2 alpha and ca9 stromal-positive crcs was associated with wild-type tp53 (p=0.001 and p=0.0391), but not with bnip3 methylation. |
2008-09-17 |
2023-08-12 |
Not clear |